Incidence and management of neutropenia in patients undergoing the AC-T protocol in the adjuvant treatment of breast cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/16018 |
Resumo: | Breast cancer is the most common tumor among women. The introduction of adjuvant systemic antineoplastic chemotherapy has the benefits of reducing the risk of recurrence and mortality from breast cancer. However, intrinsic to all chemotherapy, adverse reactions are observed, including chemotherapy-induced neutropenia, an incident reaction clearly related to febrile neutropenia events. Such events can have a significant impact on hospital costs and compromise the objective of adjuvant chemotherapy treatment. In a cross-sectional, descriptive, quantitative and retrospective study, 289 female patients with breast cancer and undergoing systemic chemotherapy adjuvant with the AC-T protocol, were evaluated in order to describe the incidence of neutropenia and identify the managements performed to maintain the treatment use. The gross incidence of neutropenia was 52.2% during the application of CA (doxorubicin and cyclophosphamide), 26.9% during the application of T (docetaxel) in patients who did not undergo primary prophylaxis (PP), and 15, 1% during application of T at the patients who made PP. Among the identified managements, use of antibiotic therapy (25.4%), use of granulocyte colony stimulating factors (23%) and postponement of the cycle (20.3%) were the most observed. The occurrence of neutropenia events during chemotherapy for breast cancer is imminent. However, it can lead to changes in the regimen that can compromise treatment. In this study, the occurrence of neutropenia points to the need to define protocols for the use of PP and management of the adverse reaction. |
id |
UNIFEI_d9a5f7bd6da666963f7d04f17ad26b0b |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/16018 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Incidence and management of neutropenia in patients undergoing the AC-T protocol in the adjuvant treatment of breast cancer Incidencia y manejo de la neutropenia en pacientes sometidas al protocolo AC-T en el tratamiento adyuvante del cáncer de mamaIncidência e manejo da neutropenia em pacientes submetidas ao protocolo AC-T no tratamento adjuvante de câncer de mamaBreast NeoplasmsNeutropeniaChemotherapy-Induced Febrile NeutropeniaDrug-related side effects and adverse reactions.Neoplasias de la MamaNeutropeniaNeutropenia Febril Inducida por QuimioterapiaEfectos colaterales y reacciones adversas relacionados con medicamentos.Neoplasias da MamaNeutropeniaNeutropenia Febril Induzida por QuimioterapiaEfeitos colaterais e reações adversas relacionados a medicamentos.Breast cancer is the most common tumor among women. The introduction of adjuvant systemic antineoplastic chemotherapy has the benefits of reducing the risk of recurrence and mortality from breast cancer. However, intrinsic to all chemotherapy, adverse reactions are observed, including chemotherapy-induced neutropenia, an incident reaction clearly related to febrile neutropenia events. Such events can have a significant impact on hospital costs and compromise the objective of adjuvant chemotherapy treatment. In a cross-sectional, descriptive, quantitative and retrospective study, 289 female patients with breast cancer and undergoing systemic chemotherapy adjuvant with the AC-T protocol, were evaluated in order to describe the incidence of neutropenia and identify the managements performed to maintain the treatment use. The gross incidence of neutropenia was 52.2% during the application of CA (doxorubicin and cyclophosphamide), 26.9% during the application of T (docetaxel) in patients who did not undergo primary prophylaxis (PP), and 15, 1% during application of T at the patients who made PP. Among the identified managements, use of antibiotic therapy (25.4%), use of granulocyte colony stimulating factors (23%) and postponement of the cycle (20.3%) were the most observed. The occurrence of neutropenia events during chemotherapy for breast cancer is imminent. However, it can lead to changes in the regimen that can compromise treatment. In this study, the occurrence of neutropenia points to the need to define protocols for the use of PP and management of the adverse reaction.El cáncer de mama es el tumor más común entre las mujeres. La introducción de la quimioterapia antineoplásica sistémica adyuvante tiene los beneficios de reducir el riesgo de recurrencia y mortalidad por cáncer de mama. Sin embargo, intrínsecas a toda quimioterapia, se observan reacciones adversas, incluida la neutropenia inducida por quimioterapia, una reacción incidente claramente relacionada con eventos de neutropenia febril. Tales eventos pueden tener un impacto significativo en los costos hospitalarios y comprometer el objetivo del tratamiento de quimioterapia adyuvante. En un estudio transversal, descriptivo, cuantitativo y retrospectivo, se evaluaron 289 pacientes femeninas con cáncer de mama y sometidas a quimioterapia sistémica adyuvante con el protocolo AC-T, con el fin de describir la incidencia de neutropenia e identificar los manejos realizados para mantener el tratamiento. usar. La incidencia bruta de neutropenia fue del 52,2% durante la aplicación de AC (doxorrubicina y ciclofosfamida), del 26,9% durante la aplicación de T (docetaxel) en pacientes que no se sometieron a profilaxis primaria (PP) y del 15,1% durante la aplicación de T a los pacientes que hicieron PP. Entre los manejos identificados, el uso de terapia antibiótica (25,4%), el uso de factores estimulantes de colonias de granulocitos (23%) y el aplazamiento del ciclo (20,3%) fueron los más observados. La aparición de eventos de neutropenia durante la quimioterapia para el cáncer de mama es inminente. Sin embargo, puede provocar cambios en el régimen que pueden comprometer el tratamiento. En este estudio, la aparición de neutropenia apunta a la necesidad de definir protocolos para el uso de PP y manejo de la reacción adversa.O câncer de mama é o tumor mais incidente entre mulheres. A introdução da quimioterapia antineoplásica sistêmica adjuvante trouxe como benefícios a redução do risco de recorrência e mortalidade por câncer de mama. Porém, intrínseca a toda quimioterapia observa-se a ocorrência de reações adversas, entre elas a neutropenia induzida por quimioterapia, uma reação incidente claramente relacionada a eventos de neutropenia febril. Tais eventos podem gerar impacto significativo nos custos hospitalares e comprometer o objetivo do tratamento quimioterápico adjuvante. Em estudo transversal, descritivo, quantitativo e retrospectivo, 289 pacientes do sexo feminino com câncer de mama e em tratamento quimioterápico sistêmico adjuvante com o protocolo AC-T, foram avaliadas de modo a descrever a incidência de neutropenia e identificar os manejos realizados para manutenção da utilização do tratamento. A incidência bruta de neutropenia foi de 52,2% durante a aplicação de AC (doxorrubicina e ciclofosfamida), de 26,9% durante a aplicação de T (docetaxel) nos pacientes que não fizeram profilaxia primária (PP), e de 15,1% durante a aplicação de T nos pacientes que fizeram PP. Entre os manejos identificados, uso de antibioticoterapia (25,4%), uso de fatores estimuladores de colônia de granulócitos (23%) e adiamento de ciclo (20,3%) foram os mais observados. A ocorrência de eventos de neutropenia ao longo do tratamento quimioterápico para câncer de mama é iminente. Todavia, pode levar a alterações no regime que podem comprometer o tratamento. Neste estudo, a ocorrência de neutropenia, aponta para a necessidade de definir protocolos de utilização de PP e manejo da reação adversa.Research, Society and Development2021-06-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1601810.33448/rsd-v10i6.16018Research, Society and Development; Vol. 10 No. 6; e48210616018Research, Society and Development; Vol. 10 Núm. 6; e48210616018Research, Society and Development; v. 10 n. 6; e482106160182525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/16018/14320Copyright (c) 2021 Luana do Amaral Brasileiro; Júlia Mouta de Oliveira; Selma Rodrigues de Castilhohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBrasileiro, Luana do AmaralOliveira, Júlia Mouta de Castilho, Selma Rodrigues de2021-06-10T22:51:46Zoai:ojs.pkp.sfu.ca:article/16018Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:36:41.762789Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Incidence and management of neutropenia in patients undergoing the AC-T protocol in the adjuvant treatment of breast cancer Incidencia y manejo de la neutropenia en pacientes sometidas al protocolo AC-T en el tratamiento adyuvante del cáncer de mama Incidência e manejo da neutropenia em pacientes submetidas ao protocolo AC-T no tratamento adjuvante de câncer de mama |
title |
Incidence and management of neutropenia in patients undergoing the AC-T protocol in the adjuvant treatment of breast cancer |
spellingShingle |
Incidence and management of neutropenia in patients undergoing the AC-T protocol in the adjuvant treatment of breast cancer Brasileiro, Luana do Amaral Breast Neoplasms Neutropenia Chemotherapy-Induced Febrile Neutropenia Drug-related side effects and adverse reactions. Neoplasias de la Mama Neutropenia Neutropenia Febril Inducida por Quimioterapia Efectos colaterales y reacciones adversas relacionados con medicamentos. Neoplasias da Mama Neutropenia Neutropenia Febril Induzida por Quimioterapia Efeitos colaterais e reações adversas relacionados a medicamentos. |
title_short |
Incidence and management of neutropenia in patients undergoing the AC-T protocol in the adjuvant treatment of breast cancer |
title_full |
Incidence and management of neutropenia in patients undergoing the AC-T protocol in the adjuvant treatment of breast cancer |
title_fullStr |
Incidence and management of neutropenia in patients undergoing the AC-T protocol in the adjuvant treatment of breast cancer |
title_full_unstemmed |
Incidence and management of neutropenia in patients undergoing the AC-T protocol in the adjuvant treatment of breast cancer |
title_sort |
Incidence and management of neutropenia in patients undergoing the AC-T protocol in the adjuvant treatment of breast cancer |
author |
Brasileiro, Luana do Amaral |
author_facet |
Brasileiro, Luana do Amaral Oliveira, Júlia Mouta de Castilho, Selma Rodrigues de |
author_role |
author |
author2 |
Oliveira, Júlia Mouta de Castilho, Selma Rodrigues de |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Brasileiro, Luana do Amaral Oliveira, Júlia Mouta de Castilho, Selma Rodrigues de |
dc.subject.por.fl_str_mv |
Breast Neoplasms Neutropenia Chemotherapy-Induced Febrile Neutropenia Drug-related side effects and adverse reactions. Neoplasias de la Mama Neutropenia Neutropenia Febril Inducida por Quimioterapia Efectos colaterales y reacciones adversas relacionados con medicamentos. Neoplasias da Mama Neutropenia Neutropenia Febril Induzida por Quimioterapia Efeitos colaterais e reações adversas relacionados a medicamentos. |
topic |
Breast Neoplasms Neutropenia Chemotherapy-Induced Febrile Neutropenia Drug-related side effects and adverse reactions. Neoplasias de la Mama Neutropenia Neutropenia Febril Inducida por Quimioterapia Efectos colaterales y reacciones adversas relacionados con medicamentos. Neoplasias da Mama Neutropenia Neutropenia Febril Induzida por Quimioterapia Efeitos colaterais e reações adversas relacionados a medicamentos. |
description |
Breast cancer is the most common tumor among women. The introduction of adjuvant systemic antineoplastic chemotherapy has the benefits of reducing the risk of recurrence and mortality from breast cancer. However, intrinsic to all chemotherapy, adverse reactions are observed, including chemotherapy-induced neutropenia, an incident reaction clearly related to febrile neutropenia events. Such events can have a significant impact on hospital costs and compromise the objective of adjuvant chemotherapy treatment. In a cross-sectional, descriptive, quantitative and retrospective study, 289 female patients with breast cancer and undergoing systemic chemotherapy adjuvant with the AC-T protocol, were evaluated in order to describe the incidence of neutropenia and identify the managements performed to maintain the treatment use. The gross incidence of neutropenia was 52.2% during the application of CA (doxorubicin and cyclophosphamide), 26.9% during the application of T (docetaxel) in patients who did not undergo primary prophylaxis (PP), and 15, 1% during application of T at the patients who made PP. Among the identified managements, use of antibiotic therapy (25.4%), use of granulocyte colony stimulating factors (23%) and postponement of the cycle (20.3%) were the most observed. The occurrence of neutropenia events during chemotherapy for breast cancer is imminent. However, it can lead to changes in the regimen that can compromise treatment. In this study, the occurrence of neutropenia points to the need to define protocols for the use of PP and management of the adverse reaction. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-07 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/16018 10.33448/rsd-v10i6.16018 |
url |
https://rsdjournal.org/index.php/rsd/article/view/16018 |
identifier_str_mv |
10.33448/rsd-v10i6.16018 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/16018/14320 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 6; e48210616018 Research, Society and Development; Vol. 10 Núm. 6; e48210616018 Research, Society and Development; v. 10 n. 6; e48210616018 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052678958743552 |